Lexicon Pharmaceuticals, Inc. to Post FY2027 Earnings of $0.10 Per Share, Leerink Partnrs Forecasts (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Investment analysts at Leerink Partnrs upped their FY2027 earnings per share estimates for shares of Lexicon Pharmaceuticals in a research report issued to clients and investors on Friday, May 3rd. Leerink Partnrs analyst R. Ruiz now expects that the biopharmaceutical company will post earnings of $0.10 per share for the year, up from their prior forecast of $0.07. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share.

Other analysts have also recently issued research reports about the company. SVB Leerink began coverage on Lexicon Pharmaceuticals in a research report on Tuesday, April 30th. They issued an “outperform” rating and a $5.00 target price for the company. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday. Finally, StockNews.com upgraded shares of Lexicon Pharmaceuticals to a “sell” rating in a report on Wednesday, May 1st.

Lexicon Pharmaceuticals Stock Up 5.2 %

Shares of NASDAQ:LXRX opened at $1.83 on Monday. Lexicon Pharmaceuticals has a 52 week low of $0.92 and a 52 week high of $3.73. The company has a debt-to-equity ratio of 0.35, a quick ratio of 15.56 and a current ratio of 15.58. The company has a market cap of $450.62 million, a PE ratio of -2.20 and a beta of 1.38. The firm has a 50 day simple moving average of $2.09 and a 200 day simple moving average of $1.75.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 8,311.12% and a negative return on equity of 108.54%.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in LXRX. BVF Inc. IL increased its holdings in Lexicon Pharmaceuticals by 22.2% in the fourth quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock worth $37,387,000 after buying an additional 4,440,300 shares during the last quarter. SG Americas Securities LLC bought a new stake in Lexicon Pharmaceuticals in the third quarter worth approximately $64,000. KWB Wealth acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth $62,000. RPO LLC bought a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at $49,000. Finally, TIAA Trust National Association acquired a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at $29,000. 74.70% of the stock is owned by hedge funds and other institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.